Brentuximab Biosimilar – Anti-TNFRSF8 mAb – Research Grade from ProteoGenix; catalogue PX-TA1621; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Brentuximab Biosimilar is a monoclonal antibody (mAb) that targets TNFRSF8, also known as CD30. It is a biosimilar version of the therapeutic antibody brentuximab vedotin, which is used in the treatment of various types of cancer. In this article, we will provide a scientific description of the structure, activity, and application of Brentuximab Biosimilar.
Brentuximab Biosimilar is a chimeric antibody, meaning it is composed of both human and non-human components. It is made up of a human IgG1 constant region and a mouse-derived variable region that specifically binds to TNFRSF8. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains.
Brentuximab Biosimilar works by binding to TNFRSF8, a protein that is overexpressed on the surface of certain cancer cells. This binding leads to the activation of immune cells, such as natural killer cells and T cells, which then target and kill the cancer cells. In addition, the antibody also induces cell death through a process known as antibody-dependent cellular cytotoxicity (ADCC), where immune cells are recruited to kill the cancer cells.
Brentuximab Biosimilar has been approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It is typically used in combination with chemotherapy or as a standalone treatment for patients who have relapsed or are refractory to other therapies. In addition, Brentuximab Biosimilar is also being studied for its potential in treating other types of cancer, such as non-Hodgkin lymphoma and solid tumors.
Brentuximab Biosimilar is a chimeric monoclonal antibody that targets TNFRSF8 and is used in the treatment of certain types of cancer. Its structure, activity, and application make it a promising therapeutic option for patients with relapsed or refractory cancer. Further research is being conducted to explore its potential in treating other types of cancer and to improve its efficacy and safety profile.
antibody, therapeutic target, Brentuximab Biosimilar, Anti-TNFRSF8 mAb, research grade, structure, activity, application, cancer, Hodgkin lymphoma, systemic anaplastic large cell lymphoma, non-Hodgkin lymphoma, solid tumors.
ProteoGenix catalogue number PX-TA1621. For research use only.
Target: Brentuximab Biosimilar – Anti-TNFRSF8 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer pH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Brentuximab Biosimilar – Anti-TNFRSF8 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
